• Home
  • News
  • CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build  a site extension at the Bubendorf site in Switzerland.  

The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).

“We are grateful for the trust our customer has placed in us by deciding to support the Bubendorf site extension. Their investment will enable the creation of a state-of-the art facility that will benefit them directly,” said Pascal Villemagne, VP sales and Marketing, CARBOGEN AMCIS. “This joint investment cements our working relationship over the long term and lays the foundation for a promising future.”

CARBOGEN AMCIS will produce exclusively for the signatory customer a complex highly potent drug component for a commercial antibody-drug-conjugate API. 

“The production of this intermediate involves five CARBOGEN AMCIS facilities around the world: three sites in Switzerland (Bubendof, Hunzenschwil and Aarau), one in the UK (Manchester) and one in China (Shanghai).The highly potent production element will take place in Bubendorf, in the new building extension.” Commented Mark Griffiths, CARBOGEN AMCIS CEO. “We are thrilled and honoured to collaborate with our customer on this project to treat patients of need and also proud to demonstrate our ability to integrate our global supply chain network.”

Currently, the planning phase for the building extension is underway and the Company expects to commence operations in autumn 2022.

****

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.

Dishman Carbogen Amcis Limited (imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.